Samsung Biologics has made a strategic decision to acquire PolyPeptide Group, a Swiss company known for its peptide-based active pharmaceutical ingredients, for 1.46 billion Swiss francs ($1.8 billion). Shareholders of PolyPeptide will receive 44.31 Swiss francs per share under the terms of this public tender offer, which is expected to finalize by the end of the year.
This acquisition is notable as it represents the largest biopharmaceutical merger and acquisition in South Korea's history. Samsung Biologics aims to diversify its offerings by entering the peptide therapeutics market, which is experiencing rapid growth due to increasing demand for treatments related to obesity.
Peptide therapeutics, including GLP-1 drugs that help manage appetite and blood sugar levels, are becoming increasingly important in the pharmaceutical landscape. Peter Wilden, chairman of PolyPeptide, expressed confidence in the offer, highlighting its attractiveness and immediate value for shareholders.
The acquisition will not only broaden Samsung's existing portfolio, which currently focuses on antibody drugs, but also expand its global presence through PolyPeptide's established network in countries such as Sweden, Belgium, France, the U.S., and India. Following the announcement, Samsung Biologics' shares experienced a slight decline of 1.3% in early trading